Unlocking the Potential of GPCRs for ADC-Based Oncology Therapies
- Revisiting GPCRs as viable oncology targets through the lens of mature ADC technologies, combining deep biological insight with innovative antibody design
- ADC optimization tailored to GPCR biology by balancing antigen density, expression heterogeneity, and internalization for maximal efficacy and selectivity
- Implementing a holistic design framework to match antibody properties, linker– payload chemistry, and target features to create next-generation, GPCR-directed ADC therapeutics